Conatus Pharmaceuticals Inc. (CNAT)
(Delayed Data from NSDQ)
$0.90 USD
+0.05 (5.88%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Histogen Inc. [CNAT]
Reports for Purchase
Showing records 61 - 80 ( 226 total )
Company: Histogen Inc.
Industry: Medical - Products
Healthcare -Join Us for Battle of the NASH Thrones Investor Conference in NYC on Oct. 17
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
2Q Recap: We Are Looking for ENCORE-PH to Be a Win in 4Q; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Healthcare - NASH Weekly: Our Clinicaltrials.gov tracker - Who Entered the NASH Arena?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Focus Turns to ENCORE-PH Data in 4Q18; Affirm Buy.
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
The First of Many ENCORE Catalysts Complete with ENCORE-PH Set for 4Q18
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
A Closer Look Into Its PSC Candidate at the Upcoming EASL Conference
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
POLT Misses Overall but Emricasan Still Beneficial; Reduce PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.